Large pharmaceutical companies own portfolios of approved drugs generating cash flows that fund the R&D pipeline for the next generation of medicines. The business model is structurally tied to the patent cycle: blockbuster drugs generate enormous margins during exclusivity, then face generic competition that can eliminate most of the revenue within months of patent expiry. Pipeline quality and upcoming patent cliff exposure are the most important factors in fundamental analysis. Drug pricing in the US remains the primary political risk — regulatory changes to pricing power would fundamentally alter industry economics. Mergers and acquisitions are a consistent feature, as large companies use cash flows from existing drugs to buy pipeline assets from smaller biotechs. For investors, established pharmaceutical companies typically offer attractive dividends, defensive characteristics and steady cash generation, balanced against the binary risk that key pipeline candidates fail in late-stage trials.
